Mayo Clinic: Prostatic Neoplasms trials

The registry lists 68 Prostatic Neoplasms studies with Mayo Clinic as lead sponsor. 19 are open to participants now and 11 have results posted.

Early Phase 1 6Phase 1 6Phase 2 21Phase 3 3Phase 4 2No phase 32(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialRecruitingNCT07650240Phase 2
• Screening and Staging of Benign vs Malignant Pelvic AbnormalitiesRecruitingNCT07407959
• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black MenRecruitingNCT07126548Not applicable
• Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate CancerRecruitingNCT07073794Phase 2
• Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA TrialRecruitingNCT07025369Phase 2
• Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During ProstatectomyRecruitingNCT06940271Not applicable
• Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative DiseasesRecruitingNCT06788886Not applicable
• Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate CancerRecruitingNCT06625034Phase 3
• Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black MenRecruitingNCT06541210Not applicable
• Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant MenEnrolling by invitationNCT06472817
• Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate CancerRecruitingNCT06389786Not applicable
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingNCT06378866Phase 2
• Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate CancerRecruitingNCT06325046Not applicable
• Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRIRecruitingNCT06315595
• MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate CancerRecruitingNCT05438563Not applicable
• Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer PatientsRecruitingNCT05045066Early Phase 1
• Understanding of Genetics by Men at Risk for Prostate CancerRecruitingNCT04550845Not applicable
• MR-Guided Cryoablation of Prostate Bed RecurrencesEnrolling by invitationNCT01727284Not applicable
• Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerCompletedNCT05730712Phase 2Results posted
• 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate CancerCompletedNCT05547386Phase 3Results posted
• A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate CancerActive, not recruitingNCT04190446Phase 2Results posted
• Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical ProstatectomyCompletedNCT03570827Phase 2Results posted
• Decision Aids to Improve Knowledge in Patients With Prostate CancerCompletedNCT03182998Not applicableResults posted
• Platelet Rich Plasma During Radical ProstatectomyCompletedNCT02957149Not applicableResults posted
• Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate CancerCompletedNCT02874014Phase 2Results posted
• Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical ProstatectomyTerminatedNCT00937768Phase 2Results posted
• Vaccine Therapy in Treating Patients With Non-Metastatic Prostate CancerTerminatedNCT00814892Phase 2Results posted
• Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate CancerCompletedNCT00714753Phase 2Results posted
• Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate CancerCompletedNCT00170157Phase 2Results posted
• InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer SurvivorsCompletedNCT06703996Not applicable
• iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black MenCompletedNCT06535802
• DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in UrineTerminatedNCT06347809
• Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate CancerActive, not recruitingNCT06326216
• SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate AdenocarcinomaActive, not recruitingNCT06205316Phase 3
• Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerSuspendedNCT06200103Phase 2
• Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF TrialCompletedNCT06037863Not applicable
• Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients with Prostate CancerTerminatedNCT06016504Not applicable
• Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III StudyCompletedNCT05895279Not applicable
• Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate CancerActive, not recruitingNCT05830838Not applicable
• CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene MutationsTerminatedNCT05689021Phase 2
• Expanded Access [Ga-68] PSMA-11 PET ImagingNo longer availableNCT04800068
• Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical ProstatectomyWithdrawnNCT04288336Early Phase 1
• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerCompletedNCT04067960Early Phase 1
• PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate CancerCompletedNCT03768349Early Phase 1
• Genetic Biomarker Discovery for Metastatic Prostate CancerCompletedNCT03228810
• Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate CancerCompletedNCT03159676
• Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing SurgeryWithdrawnNCT03147196Phase 2
• Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following RadiotherapyActive, not recruitingNCT03017794
• SBRT for Oligometastatic Castration-Refractory Prostate CancerCompletedNCT02816983
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1
• Focal Laser Ablation of Low to Intermediate Prostate Cancer TumorsCompletedNCT02600156Not applicable
• Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition TherapyCompletedNCT01953640
• Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or BrachytherapyCompletedNCT01777802
• MR-Guided Laser Ablation of Prostate Bed RecurrencesWithdrawnNCT01743638Not applicable
• Prospective Randomized Trial Comparing Robotic Versus Open Radical ProstatectomyTerminatedNCT01365143Phase 4
• Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow UpCompletedNCT01098552
• Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate CancerCompletedNCT01050842Early Phase 1
• Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE CollaborationCompletedNCT00987376Phase 1
• Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate CancerCompletedNCT00956228Phase 1/2
• Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation TherapyTerminatedNCT00788307Phase 1
• Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation TherapyCompletedNCT00684905Phase 2
• Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate CancerCompletedNCT00653757Phase 1/2
• Local Anesthesia for Prostate BiopsyCompletedNCT00422708Phase 4
• Exisulind Prior to Radical ProstatectomyCompletedNCT00166478Phase 2
• Exisulind Versus Placebo After Surgical Removal of the ProstateCompletedNCT00166426Phase 2
• Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00003690Phase 1
• Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid TumorsCompletedNCT00003038Phase 1